|
One Step Dementia Risk Test Kit
The test strips are manufactured in China and carry CE, NMPA, and MDA certifications, indicating compliance with both domestic and international regulatory frameworks.
Most dementia diagnostics depend on cerebrospinal fluid analysis or PET imaging—expensive, invasive, and restricted to specialist centers. The One Step Dementia Risk Test Kit breaks with that model entirely. It is a lateral flow immunochromatographic strip that detects amyloid-beta (Aβ) concentration in urine, delivering a result in ten minutes.
The test uses colloidal gold conjugated to proprietary Aβ monoclonal antibodies in a sandwich format. Sensitivity is 79.14% and specificity 91.03%, with a kappa value of 0.704 against reference methods. It is classified as an auxiliary screening device, not a diagnostic—a risk-alert tool that helps clinicians decide whether to proceed with confirmatory workup.
The intended user is the primary care or community health setting. A fresh midstream urine sample of 100 µL is applied directly to the cassette. No instrumentation, cold chain, or trained lab technician is required. That makes the test deployable in township clinics, community screening drives, and large-scale epidemiological surveys.
Target populations are defined clearly: individuals aged 45 and older, especially those with family history of dementia, cognitive complaints, cardiovascular disease, or metabolic risk factors such as hypertension and diabetes. The test captures a broad preclinical cohort, which is precisely where early intervention has the most leverage.
China’s role here is not incidental. The product originated from domestic R&D—core antibody development and polymer sandwich chemistry—and is manufactured under NMPA oversight. With an aging population projected to exceed 400 million by 2040, China is both the proving ground and the primary market for high-volume, low-cost dementia screening tools.
Pack sizes of 1, 25, and 50 tests per box suggest a procurement logic built for flexibility: single tests for clinic stocking, bulk boxes for screening campaigns. The pricing and supply chain economics are not disclosed, but the CE and MDA marks indicate export readiness into Europe and Southeast Asia.
Nothing about this kit replaces a neurologist. What it does is shift the front line of cognitive screening from tertiary hospitals to the community clinic bench—and that is where the real leverage lies.
Why it matters:
For health systems and procurement buyers, this test introduces a logistics-light screening layer compatible with existing non-invasive workflows. It lowers the cost threshold for population-level dementia risk assessment and opens a path to earlier, cheaper intervention—particularly relevant for rural and primary-care networks.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
|
|
No products in the cart.